Jose Ruben Garcia-Montes

Cajal Institute, CSIC, Madrid 
"Jose Garcia-Montes"
Mean distance: 14.65 (cluster 46)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Ruiz-DeDiego I, Fasano S, Solís O, et al. (2018) Genetic enhancement of Ras-ERK pathway does not aggravate L-DOPA-induced dyskinesia in mice but prevents the decrease induced by lovastatin. Scientific Reports. 8: 15381
García-Montes JR, Solís O, Enríquez-Traba J, et al. (2018) Genetic Knockdown of mGluR5 in Striatal D1R-Containing Neurons Attenuates L-DOPA-Induced Dyskinesia in Aphakia Mice. Molecular Neurobiology
Suarez LM, Alberquilla S, García-Montes JR, et al. (2018) Differential synaptic remodeling by dopamine in direct and indirect striatal projection neurons in Pitx3-/- mice, a genetic model of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience
Solís O, García-Montes JR, Garcia-Sanz P, et al. (2017) Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice. Neurobiology of Disease
Solís O, Garcia-Montes JR, González-Granillo A, et al. (2015) Dopamine D3 Receptor Modulates l-DOPA-Induced Dyskinesia by Targeting D1 Receptor-Mediated Striatal Signaling. Cerebral Cortex (New York, N.Y. : 1991)
Moratalla R, Khairnar A, Simola N, et al. (2015) Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms. Progress in Neurobiology
Heumann R, Moratalla R, Herrero MT, et al. (2014) Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions. Journal of Neurochemistry. 130: 472-89
García-Montes J, Boronat-García A, Drucker-Colín R. (2012) Pharmacological strategies for Parkinson's disease Health. 2012: 1153-1166
See more...